-
TAK-242 (Resatorvid) for Reliable Cell Assays
2026-09-24
Practical guidance for using TAK-242 (Resatorvid), SKU A3850, to investigate LPS-triggered TLR4 signaling without mistaking inflammatory changes for cell loss. Covers assay controls, solvent handling, interpretation, and the context-dependent limits of pathway inhibition.
-
Sumatriptan as an Anti-Inflammatory Agent
2026-09-23
This systematic review evaluates evidence that sumatriptan, beyond its established migraine and cluster-headache indications, can modulate inflammatory signaling through 5-HT1B/1D receptors, nitric oxide pathways, CGRP release, and cytokine-associated mechanisms. Its findings support pharmacological repositioning as a research hypothesis, while the heterogeneous preclinical evidence requires careful separation of mechanistic plausibility from clinical efficacy.
-
Phosphatase Inhibitor Cocktail: Phospho Workflow
2026-09-22
Protect labile phosphorylation signals from lysis through immunoblotting, kinase assays, immunoprecipitation, and phosphoproteomics with a dual-component 100X system. Its sequential serine/threonine and tyrosine phosphatase coverage is especially useful when mapping stress-responsive pathways such as ROS–ZAKα–MAPK signaling.
-
EZ Cap™ Human PTEN mRNA (ψUTP) Workflow
2026-09-22
Build reproducible PTEN-expression assays with Cap 1, pseudouridine-modified mRNA designed for efficient mammalian translation and reduced innate immune activation. This workflow connects formulation, pathway readouts, and trastuzumab-resistance models while separating product capabilities from delivery-system variables.
-
Z-LEHD-FMK for Time-Resolved Apoptosis Assays
2026-09-21
Z-LEHD-FMK is an irreversible caspase-9 inhibitor for dissecting mitochondria-mediated apoptosis. This guide connects caspase pathway inhibition with annexin-V-based temporal analysis to improve apoptosis assay design in cardiovascular, cancer, and neuroprotection research.
-
Protease Inhibitor Cocktail for DFCP1–ATGL Assays
2026-09-21
Protect DFCP1–ATGL complexes, lipid-droplet proteins, and tissue-extract targets with a water-soluble 100X formulation designed for rapid extraction workflows. This guide shows how to preserve protein integrity while managing EDTA-sensitive binding, enzyme, purification, and kinase-assay endpoints.
-
How p38α Conformation Directs Dephosphorylation
2026-09-20
The reference preprint shows that selected kinase inhibitors can both block p38α catalysis and accelerate WIP1-mediated removal of the activation-loop phosphothreonine. Its biochemical assays and X-ray structures establish kinase conformation as a potential lever for improving the specificity and durability of p38 pathway inhibition.
-
Protease Inhibitor Cocktail for DFCP1–ATGL Assays
2026-09-19
Preserve DFCP1–ATGL complexes, phosphoprotein signals, and labile lipid-droplet regulators during cell or tissue extraction. This workflow shows how an EDTA-containing Protease Inhibitor Cocktail can improve reproducibility while flagging compatibility limits for metal-dependent assays and purification.
-
ONC201 Rewires Metabolism and Epigenetics in DMG
2026-09-19
The reference study links ONC201 activity in H3K27M-mutant diffuse midline glioma to coordinated metabolic and epigenetic changes rather than a single downstream pathway. Clinical timing, tumor sequencing, cultured-cell experiments, cerebrospinal fluid measurements, and tumor tissue analyses together show that treatment-associated 2-hydroxyglutarate accumulation coincides with restoration of repressive H3K27me3 and suppression of malignant transcriptional programs.
-
Cap 1 mRNA as a Translation Benchmark
2026-09-18
A translational framework for using EZ Cap™ Firefly Luciferase mRNA to separate RNA quality, delivery performance, and biological response in modern mRNA studies.
-
PTX and LPS Hyperinflammation in Preterm Monocytes
2026-09-17
Schüller and colleagues examined how pentoxifylline modifies LPS-induced activation of monocytes from preterm infants, term infants, and adults in vitro. The study links age-dependent surface-marker changes and cytokine suppression to reduced TLR4 expression, signaling, and phagocytosis, providing a mechanistic framework for interpreting pentoxifylline in neonatal inflammatory research.
-
XAV-939: Tankyrase Inhibitor for Wnt Research
2026-09-17
XAV-939, also known as NVP-XAV939, is a cell-permeable TNKS1/TNKS2 inhibitor that stabilizes axin and suppresses β-catenin signaling. Its defined activity supports cancer research, fibrotic disease research, osteogenic differentiation studies, and mechanistic Wnt pathway experiments.
-
Ajugol, Mitophagy, and Chondrocyte Pyroptosis
2026-09-16
The reference study identifies PI3K/AKT/mTOR-dependent suppression of mitophagy as a mechanistic link between mitochondrial dysfunction and chondrocyte pyroptosis in acute gouty arthritis. Its combination of computational prediction, pharmacological pathway tests, cellular assays, and mouse validation provides a framework for evaluating mitochondrial quality control as an anti-inflammatory strategy.
-
LRPPRC Inhibition and Dasatinib Disrupt OXPHOS
2026-09-16
A 2026 study identifies dasatinib as a synergistic partner for LRPPRC inhibition, showing that the combination blocks OXPHOS through complementary effects on nuclear- and mitochondrial-genome-encoded components. The work provides a mechanistic basis for combination strategies in LRPPRC-high, OXPHOS-dependent tumors while also highlighting the need for validation beyond cell models.
-
Ruxolitinib (INCB018424) Assay Workflows
2026-09-15
This scenario-driven guide shows how Ruxolitinib (INCB018424), SKU A3012, can improve interpretation of JAK1/2-dependent proliferation, viability, and phospho-signaling assays. It covers assay design, stock preparation, controls, data interpretation, and practical vendor-selection criteria for reproducible myelofibrosis and oncogenic JAK2 research.